详情页 - 首都医科大学宣武医院知识库

资源类型：

文章类型：

作者：

Ronald B Postuma[2] * ; Daniela Berg[1] * ; Charles H Adler[3] ; Bastiaan R Bloem,[4] ; Piu Chan,[5]

; Günther Deuschl,[6] ; Thomas Gasser,[1] ; Christopher G Goetz,[7] ; Glenda Halliday,[8] ; Lawrence Joseph,[9] ; Anthony E Lang[10] ; Inga Liepelt-Scarfone,[1] ; Irene Litvan,[11] ; Kenneth Marek,[1,12] ; Wolfgang Oertel,[13] ; C Warren Olanow,[14] ; Werner Poewe,[15] ; Matthew Stern[16] ;

机构： [1]Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany [2]Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada [3]The Parkinson’s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale [4]Department of Neurology, Radboud university medical center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands [5]Xuanwu Hospital of Capitol of Medical University, Beijing, Peoples Republic of China [6]Department of Neurology, Christian-Albrechts University, Kiel, Germany [7]Rush University Medical Center, Chicago, IL, USA [8]Neuroscience Research Australia and University of New South Wales, Randwick, Australia [9]Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada [10]Division of Neurology, Toronto Western Hospital, Toronto, Ontario, Canada [11]Department of Neurosciences, UC San Diego, La Jolla, California, USA [12]Institute for Neurodegenerative Disorders, New Haven, CT, USA [13]Department of Neurology, Philipps University of Marburg, Marburg, Germany [14]Department of Neurology, The Mount Sinai Hospital, New York, NY, USA [15]Department of Neurology, Innsbruck Medical University, Innsbruck, Austria [16]Penn Neurological Institute, Philadelphia, Pennsylvania, USA

出处：

DOI：

ISSN：

基金：

DB received funds for consultancy/speaking from UCB pharma, Teva, Novartis, and Lundbeck; and grants from the Michael J Fox Foundation, Janssen Pharmaceuticals, the German Parkinsons’ disease Association, Parkinson Fonds Deutschland, Teva, and the European Union. RBP received grants from the Fonds de la Recherche en Sante Quebec, the Canadian Institute of Health Research, the Parkinson Society of Canada, the Weston-Garfi eld Foundation, the Michael J Fox foundation, and the Webster Foundation; funding for consultancy from Biotie and Roche; and speaker fees from Novartis Canada and Teva Neurosciences. CHA has received research funding from Phytopharm, Avid Radiopharmaceuticals, the Michael J Fox Foundation, the National Institutes of Health, US Department of Defense, and the Arizona Biomedical Research Foundation; and consulting fees from Abbvie, Acadia, Allergan, Impax, Ipsen, Lily, Lundbeck, Merz, Novartis, Teva, and Xenoport. BRB received grant funding from the Netherlands Organization for Scientifi c Research, Prinses Beatrix Foundation, Stichting Parkinson Fonds, Michael J Fox Foundation, Parkinson Vereniging, and the National Parkinson Foundation; and consultancy/speaker fees from Danone, Zambon, Abbvie, and Teva. PC received grant support from the Ministry of Science and Technology of China. CGG received funds for consultancy from Acadia (Deborah Wood Associates), AstraZeneca, Avanir, Boston Scientifi c, Ceregene, Clearview, Health Advances, Chelsea Pharmaceuticals (Link Medical Communications), ICON Pricespective LLC, Med-IQ Educational Services, Neurocrine, Pfi zer, Pricespective, Teva, and WPP Group Kantor Health LLC; royalties from Oxford University Press, Elsevier Publishers, Wolters Kluwer Health-Lippincott, and Wilkins and Wilkins; grant support from National Institutes of Health, Michael J Fox Foundation, and the Movement Disorders Society; travel support from Ceregene; and is a board member for Acadia and AstraZeneca. CGG directs the Rush Parkinson’s Disease Research Center that receives support from the Parkinson’s Disease Foundation; he directs the translation programme for the Movement Disorder Society Unifi ed Parkinson’s Disease Rating Scale and the Unifi ed Dyskinesia Rating Scale and receives funds from the International Parkinson and Movement Disorder Society for this eff ort. GH has stock ownership in Cochlear and NIB Holdings; has received consultancy funds from the National Health and Research Council, has received royalties from Academic press, Elsevier, and Oxford University Press; and has grants from National Health and Research Council, Michael J Fox Foundation, Shake-it-Up Australia, Parkinson’s NSW, and University of New South Wales. AEL received consultancy from Novartis, Teva, Abbott, Allon Therapeutics, Avanir Pharmaceuticals, Merck, Medtronic, AbbVie, Biogen Idec, Boehringer Ingelheim, NeuroPhage Pharmaceuticals, Centogene, Ceregene; expert testimony regarding welding rods; has grants/grants pending with Canadian Institutes of Health Research, Michael J Fox Foundation, National Parkinson Foundation, Brain Canada, W Garfi eld Weston Foundation, Parkinson Society Canada, Tourette Syndrome Association, Edmond J Safra Philanthropic Foundation, and Ontario Brain Institute; and has royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. IL has served on advisory boards for Pfi zer, Teva Neuroscience, Merz pharmaceuticals, Northera, Bristol-Myers Squibb, and has been a consultant for UCB pharma; she has received grants the National Institute of Health, the Parkinson Study Group, the Michael J Fox Foundation, CBD solutions-CurePSP, Teva Pharmaceuticals, and AVID Pharmaceuticals. KM received consultancy from Molecular Imaging, Pfi zer, GE Healthcare, Merck, Lilly, Bristol-Myers Squibb, Piramal, Prothena, Roche, Oxford Biomedica, Lysosomal Therapeutic. WO is Senior Research Professor of the Charitable Hertie Foundation, Frankfurt/Main Germany. CWO received consultancy from Abbvie, Lilly/Medtronic, LUndbeck, Newron, Novartis, Teva, and Zambon, and owns stock in Clintrex, and has grant support from the Michael J Fox Foundation, the National Space Board Research Institute, and Zambon. WP received personal fees from Abbvie, Allergan, Astra Zeneca, BIAL Pharamaceuticals, Boehringer-Ingelheim, Boston Scientifi c, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD Pharmaceuticals, Merck-Serono, Merz, Novartis, Orion Pharma, Teva, University California Berkeley, and Zambon; and received royalties from Wiley Blackwell, Oxford University Press, and Cambridge University Press. MS received consultancy fees from Teva, Merz, Adamas, and Civitas; stock/stock options from Civitas and Adamas; and travel expenses from the International Parkinson and Movement Disorder Society. GD and LJ declare no competing interests. TGasser and IL-S declare no competing interests.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 1 区

医学

小类 | 1 区临床神经病学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区临床神经病学

JCR分区：

出版当年[2014]版：

Q1 CLINICAL NEUROLOGY

最新[2023]版：

Q1 CLINICAL NEUROLOGY

第一作者：

第一作者机构： [2]Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada

共同第一作者：

通讯作者：

通讯机构： [2]Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada

推荐引用方式(GB/T 7714)：

APA：

MLA：

The new definition and diagnostic criteria of Parkinson's disease

文献详情